u/nordic_pricing

norway is the outlier and not in a good way. same product, roughly 2.4x the cheapest EU price i track.

qingdao to stockholm in eight days twice, if you want another row. DHL.

Not convinced — the US threads are a different system entirely and importing their advice here does real harm.

That is area percent from a certificate, not the amount of peptide in the vial. Two different numbers and a very common mix-up.

I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your nausea pattern is a guess.

Gently disagree with the framing — nothing has gone wrong. Week 3 looking flat is the ordinary experience.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Agree. The verification log is the part with the checkable facts in it; the number at the top is just a summary of a lot of averaging.

zepbound and mounjaro are the same compound with different labels

not approved anywhere, which is the single most important fact in this board

The order I actually check things in, for anyone building a process rather than asking about one supplier.

First, the record: source page, verification log, and how many separate lots have been tested rather than how many tests exist. Second, the paperwork: ask for a batch-specific certificate and see what comes back and how fast. Third, the logistics: quoted lead time, minimum quantity, which lines are held in regional stock. Fourth, buy small and test it yourself.

Nothing in that list is exotic and all of it is answerable before you spend real money. Most of the disappointment posts on this board skipped step two.

On means, which this board treats as targets and which are nothing of the sort.

A reported mean body weight change is the centre of a distribution that in these trials is very wide. Substantial numbers of participants did much better, and substantial numbers did considerably worse while remaining on the drug and in the analysis.

Quoting the mean as an expectation therefore misleads in both directions: it makes ordinary results look like failures and it makes exceptional results look normal. If a paper publishes the distribution — and several do, in the appendix — look at that instead. It is far more informative than the number in the abstract.

NHS pathway or private prescription?

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

Research-use-only material is not approved for human use.

Saving this one. It is the clearest statement of the stall problem I have read here.

a domain registered last month with a decade of testimonials is the whole tell

sulphur burps are the signature complaint and they are not dangerous

Correction: the starting dose is a tolerance step rather than a treatment dose. The distinction is the answer to the question above.

Yes — nobody here is your clinician, and the good answers on this board all end with that.

Agreed, and for anyone finding this later: that is the normal experience, not a warning sign.

What week are you in?

Correction: the starting dose is a tolerance step rather than a treatment dose. The distinction is the answer to the question above.

Pointing this one at a pharmacist locally. Eligibility questions have national answers we cannot give.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

How many separate lots is that across?

arne_nyberg is describing the batch record test and it is the fastest signal available before you spend anything.

The online consultation asked me three questions, none of them about my history. I did not go ahead.

wait for phase 3 before you argue about rankings

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

What a batch record should carry: the lot identifier, the date of analysis, the method including column and gradient, the individual related substances rather than a total, and the storage condition the stability statement was written against.

Switching from semaglutide, since three people asked in this thread alone.

There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.

None of that is a recommendation. It is what the threads say, and the threads are not a clinic.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

zepbound and mounjaro are the same compound with different labels

On means, which this board treats as targets and which are nothing of the sort.

A reported mean body weight change is the centre of a distribution that in these trials is very wide. Substantial numbers of participants did much better, and substantial numbers did considerably worse while remaining on the drug and in the analysis.

Quoting the mean as an expectation therefore misleads in both directions: it makes ordinary results look like failures and it makes exceptional results look normal. If a paper publishes the distribution — and several do, in the appendix — look at that instead. It is far more informative than the number in the abstract.

Pharmacy link removed. No links of any kind here, in any country, for any reason.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Country added to the title — the answers differ across the union and the thread is unusable without it.

nobody here can tell you what dose to be on

I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your reflux pattern is a guess.

Pharmacy link removed. No links of any kind here, in any country, for any reason.